Cemiplimab in der Anwendung bei hochbetagten Patienten

Zusammenfassung

Wir berichten über den erfolgreichen Einsatz von Cemiplimab bei insgesamt 23 hochbetagten Patienten mit fortgeschrittenen und/oder metastasierten Plattenepithelkarzinomen, die bei guter Verträglichkeit trotz Komorbiditäten nephrogener oder kardialer Genese, Diabetes und auch bei Vorliegen von Zweitmalignomen ein gutes Ansprechen boten.

Eine komplette Remission konnte bei 10 Patienten, eine partielle Remission bei 8 Patienten erreicht werden. 6 der 7 Patienten mit Zweittumoren zeigten ein Ansprechen. Ein Ansprechen zeichnete sich meist schon nach wenigen Therapiezyklen ab.

Abstract

We report on the successful use of cemiplimab in highly elderly patients with advanced and/ or metastatic squamous cell carcinomas, which offered good response and good tolerability despite comorbidities such as nephrogenic, cardiac genesis, diabetes and also in the presence of concomitant malignancies. A complete remission was achieved in 10 patients, a partial remission in 8 patients. 6 out 7 patients who presented a concomitant malignancy showed a response. A good response was already seen after a few therapy courses.

Publikationsverlauf

Artikel online veröffentlicht:
22. April 2021

• Literatur

• 1 Leiter U, Keim U, Eigentler T. et al. Incidence, mortality, and trends of nonmelanoma skin cancer in Germany. J Invest Dermatol 2017; 137: 1860e7
• 2 Schmitz L, Gambichler T, Gupta G. et al. Actinic keratosis area and severity index (AKASI) is associated with the incidence of squamous cell carcinoma. J Eur Acad Dermatol Venereol 2018; 32: 752-756 DOI: 10.1111/jdv.14682.
• 3 Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012; 166: 1069-1080
• 4 Stang A, Khil L, Kajuter H. et al. Incidence and mortality for cutaneous squamous cell carcinoma: a comparison across three continents. J Eur Acad Dermatol Venereol 2019; 33 (Suppl. 08) 6-10
• 5 Leitlinienprogramm Onkologie, S3 Aktinische Keratose und Plattenepithelkarzinom der Haut, Version 1.1. März 2020
• 6 Amaral T, Osewold M, Presser D. et al. Advanced cutaneous squamous cell carcinoma: a real world data of patient profiles and treatment patterns. J Eur Acad Dermatol Venereol 2019; 33 (Suppl. 08) 44-51
• 7 Stratigos A, Garbe C, Lebbe C. et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer 2015; 51: 1989-2007
• 8 Hillen U, Leiter U, Haase S. et al. Advanced cutaneous squamous cell carcinoma: a retrospective analysis of patient profiles and treatment patterns – Results of a non-interventional study of the DeCOG. Eur J Cancer 2018; 96: 34-43
• 9 Maubec E, Petrow P, Scheer-Senyarich I. et al. Phase II Study of Cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011; 29: 3419-3436
• 10 Grob JJ, Gonzalez R, Basset-Seguin N. et al. Pembrolizumab monotherapy for recurrent of metastatic cutaneous squamous cell carcinoma: a single arm phase II trial (Keynote 629). J Clin Oncol 2020; 38: 2916-2925
• 11 Migden MR, Khushalani NI, Chang ALS. et al. Primary analysis of phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients with locally advanced cutaneous squamous cell carcinoma, poster presented at the 2019 American Society of Clinical Oncology. Chicago, Illinois: 2019
• 12 Migden MR, Khushalani NI, Chang ALS. et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol 2020; 21: 294-305
• 13 Migden MR, Khushalani NI, Chang ALS. et al. Health-Related Quality of Life (HRQL) in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC) Treated with Cemiplimab: Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial, Poster Nr. 382, presented at American Society of Clinical Oncology (ASCO). 2020
• 14 Rischin D, Midgen MR, Lim AM. et al. Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow up, Poster Nr. 367, presented at American Society of Clinical Oncology (ASCO). 2020
• 15 Rischin D, Midgen MR, Lim AM. et al. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer 2020; 8: e000775 DOI: 10.1136/jitc-2020-000775.
• 16 Hober C. et al. Cemiplimab for advanced cutaneous squamous cell carcinoma: a real life experience, presented at ESMO, September 19–21, 2020.
• 17 Salzmann M, Leiter U, Loquai C. et al. Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. Eur J Cancer 2020; 138: 125-132
• 18 Saponara M, Pala L, Conforti F. et al. Patients with locally advanced and metastatic cutaneous squamous cell carcinoma treated with immunotherapy in era of covid-19: stop or go? Data from five Italian referral cancer centers. Ther Adv Med Oncol 2020; 12: 1758835920977002 DOI: 10.1177/1758835920977002.
• 19 Leiter U, Loquai C, Reinhardt L. et al. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patientes. J Immunother Cancer 2020; 8: e000897 DOI: 10.1136/jitc-2020-000897.